Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake

Charalambos Vlachopoulos; Iosif Koutagiar; Ioannis Skoumas; Dimitrios Terentes-Printzios; Evangelos A. Zacharis; Genovefa Kolovou; Kimon Stamatelopoulos; Loukianos S. Rallidis; Niki Katsiki; Helen Bilianou; Dimitrios Tousoulis; Constantinos Anagnostopoulos

doi:https://doi.org/10.1016/j.jcmg.2019.09.024

doi.org/10.1016/j.jcmg.2019.09.024

Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake

Charalambos Vlachopoulos

64

,

Iosif Koutagiar

11

,

..., Constantinos Anagnostopoulos

24

JACC: Cardiovascular Imaging14.00

Volume: 12, Issue: 12, Pages: 2573 - 2574

Published: Dec 1, 2019

Abstract

Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9i) reduce cardiovascular events ([1][1],[2][2]). 18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography/computed tomography (PET/CT) successfully evaluates arterial inflammation and...

Paper Fields

Paper Details

Title

Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake

DOI

doi.org/10.1016/j.jcmg.2019.09.024

Published Date

Dec 1, 2019

Journal

JACC: Cardiovascular Imaging

Volume

12

Issue

12

Pages

2573 - 2574

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History